Her om produktet (som fikk Orphan Drug staus for en ukes tid siden) Alligator har outsourcet til Henlios med 35% royalty til Alligator. Vet ikke om de også er berettiget til milestone-utbetalinger, men det skulle vi tro. Så bare så langt i innlegget 3 kurstriggere som ennå ikke er materialisert. Bør komme børsmelding fra Alligator om følgende:
Nytt för idag!
AppClon “HLX22, Expanding Development from Gastric Cancer to Breast Cancer Treatment… Expecting Various Cancer Treatment Options”
attachment - date 2025-03-26 check 33
On the 26th , AppClon announced that HLX22 is an innovative new drug with higher efficacy than existing standard treatments , and that it is also being developed as a treatment for breast cancer with high HER2 expression rates .
According to Henlius’ business report, HLX22 is a core pipeline that shows high efficacy compared to existing standard treatments . It is an antibody treatment based on AC101 , which was transferred to Abclon in 2016 , and can receive milestones for each clinical stage and royalties upon commercialization .
HLX22 is an antibody that targets a specific part of the HER2 protein . Unlike existing treatments, it affects cancer cells more precisely and efficiently by differentiating the antigen-binding site of HER2 . When bound to HER2 together with trastuzumab (HLX02), it was shown to more effectively remove the HER2 protein on the surface of cancer cells, thereby inhibiting cancer cell growth signals .
The HLX22 and trastuzumab combination therapy showed better efficacy than the existing trastuzumab and pertuzumab combination therapy in the treatment of gastric cancer, and showed therapeutic efficacy regardless of the PD-L1 expression level . In particular, severe diarrhea, which was commonly reported in existing first- line HER2 -positive gastric cancer treatments, was not observed in HLX22 , and thus, it has been positively evaluated in terms of safety .
Currently, the standard therapy for the treatment of metastatic gastric cancer and gastroesophageal junction cancer is the combination therapy of trastuzumab and chemotherapy , which was approved in 2010. It has recorded a progression-free survival period of 6.7 months , an overall survival period of 13.8 months , and a duration of response of 6.9 months . On the other hand, the HLX22 combination therapy demonstrated excellent clinical efficacy, as it did not reach the progression-free survival period , overall survival period , or duration of response based on a median follow -up period of 20.3 months .
Meanwhile, HLX22 is also being developed as a treatment for breast cancer with high HER2 expression, and its scope of application is expected to expand further . HER2 -positive breast cancer accounts for approximately 15-20% of all breast cancers, and with 2.3 million new patients occurring each year , it is considered a key market for HER2 -targeted treatments along with gastric cancer . Based on such diverse therapeutic possibilities, HLX22 is expected to present a new standard in the treatment of solid cancers .
An AppClon official said, “HLX22 has shown excellent efficacy in the treatment of gastric cancer, and is expected to play an important role in the treatment of other solid cancers such as breast cancer. We expect HLX22 to become an important treatment option in more cancer treatment markets in the future . ”
He continued, “ HLX22 ’s innovative approach has the potential to change the future paradigm of cancer treatment by more precisely blocking the growth signals of cancer cells , ” emphasizing , “ It can especially provide hope to cancer patients who have had difficulty responding to existing treatments . ”
